Concepedia

Andriy Moshyk

AM

16

Publications

3.9K

Citations

13

H-Index

2005

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Inserm

Dana-Farber Cancer Institute

Melanoma Institute Australia

Bristol-Myers Squibb (Germany)

Andriy Moshyk is an author at Bristol-Myers Squibb (United States) specializing in medicine, cancer therapeutics, and radiation oncology.

ORCID

Top concepts

Publications per year

2005–2024

16

Publications

16

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.6K citations · Full text

Depression and mortality in the visually‐impaired, community‐dwelling, elderly population of Quebec

Marie Tournier, Yola Moride, Thiérry Ducruet et al. · Acta Ophthalmologica · 2008 · 52 citations

Integrating feedback from a clinical data warehouse into practice organisation

Andrew Grant, Andriy Moshyk, Hassan Mahmoud Diab et al. · International Journal of Medical Informatics · 2005 · 45 citations

, , +15

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Georgina V. Long, Evan J. Lipson, F. Stephen Hodi et al. · Journal of Clinical Oncology · 2024 · 44 citations · Full text

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Meredith M. Regan, Charlene Mantia, Lillian Werner et al. · Journal for ImmunoTherapy of Cancer · 2021 · 33 citations · Full text

Rows per page

1–5 of 16